July 2014 |
- CureApp, Inc was established.
|
December 2014 |
- Selected for "I-Challenge! (the ICT Innovation Creation Challenge Program)" sponsored by the Ministry of Internal Affairs and Communications.
|
February 2015 |
- Procured approximately 30 million yen by raising capital through third-party allocation.
- Started clinical research on applications for treating nicotine addiction at Keio University Hospital.
|
October 2015 |
- Procured approximately 70 million yen by raising capital through third-party allocation.
- Granted the The Ministry of Economy, Trade and Industry "Monodzukuri Grant".
|
November 2015 |
- Made the decision to adopt NEDO "research and development type venture support".
|
February 2016 |
- Achieved second-class medical device manufacturing and sales business status.
|
October 2016 |
- The Department of Gastroenterology and the University of Tokyo Medical School Hospital and NASH (nonalcoholic steatohepatitis) Clinical research of therapeutic applications began.
- Obtained an Information Security Management System (ISMS).
|
January 2017 |
- Selected for the "HIYAKU Next Enterprise" Program sponsored by the Ministry of Economy, Trade and Industry (dispatched to Silicon Valley).
|
February 2017 |
- Procured approximately 380 million yen by raising capital through third-party allocation.
|
April 2017 |
- Launched the "ascure smoking cessation program" as the first series of a mobile health program for corporate users.
|
October 2017 |
- Started clinical tests on applications for treating nicotine addiction.
|
February 2018 |
- Procured approximately 1.5 billion yen by raising capital through third-party allocation.
|
March 2018 |
- Acquired the "Privacymark (P mark)," provided by JIPDEC.
|
June 2018 |
- Started clinical research on hypertension treatment applications at multiple institutions, including Jichi Medical University Hospital.
- Selected for the "J-Startup" Program sponsored by the Ministry of Economy, Trade and Industry.
|
March 2019 |
- Established CureApp North America, Inc.
|
May 2019 |
- Announced the results of Japan's first "clinical test of an app" at the American Thoracic Society 2019 International Conference.
- Announced the effectiveness of the treatment applications for nicotine addiction in smoking cessation outpatient clinics via Phase III clinical trials in Japan.
|
August 2019 |
- Procured approximately 2.3 billion yen by raising capital through third-party allocation.
|
May 2020 |
- The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan.
|
June 2020 |
- CureApp Awarded as Technology Pioneer by World Economic Forum.
|
August 2020 |
- CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups.
- Asia’s First Prescription “Digital Therapeutic” Approved in Japan ; Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval.
|
Nobember 2020 |
- Partnered with Daiichi Sankyo INC. to develop a Prescription Digital Therapeutic App for Breast Cancer
|
December 2020 |
- CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
|
March 2021 |
-
Raised over 2.1 billion yen by through an allocation of newly
issued common stock, reaching a cumulative of over 6.4 billion
yen to date.
-
Our hypertension therapeutics app, has completed a Japanese
Phase III multi-center randomized controlled trial. The research
for the app was carried out in collaboration with a team led by
Professor Kazuomi Kario at Jichi Medical University.
|
May 2021 |
- Began clinical trial for digital therapeutics for alcoholism at Okayama City Hospital in Japan
|
July 2021 |
- CureApp launches an online smoking cessation platform, ascureDr for Smoking Cessation, for health insurance associations, companies, and municipalities, which provides easier access to the therapeutic apps.
|
August 2021 |
- Selected for the Tokyo Metropolitan Government Project to Build Next-Generation Wellness Solutions. (Content related to the development of a program to prevent serious diseases, specializing in hypertension prevention)
- Presented the clinical trial results of a hypertension treatment app at ESC Congress 2021, and published the results in the European Heart Journal.
|
September 2021 |
- CureApp was selected for the Tokyo Metropolitan Government’s Startup Promotion Project, PoC Ground Tokyo.
|
October 2021 |
- CureApp’s alcoholism treatment project was selected for AMED’s Medical-Industrial Collaboration Innovation Promotion Project.
|
November 2021 |
- Added a page about sustainability efforts.
- Listed on Nikkei Trendy (a Japanese business newspaper) "2022 Hit Prediction Ranking".
- "Online Non-smoking support by instructors" and "On-line non-smoking treatment by doctor" with "POC GROUND TOKYO" in the Tokyo Metropolitan Startup Supplementary Experiment Promotion Project.
|
December 2021 |
- Partnered with a medical corporation Yumino to develop a chronic heart failure treatment app.
- Won the Minister of Economy, Trade and Industry in the 21st JAPAN Venture Awards.
- "2021 Japan Excellent Products and Service Award" Winner award.
|
April 2022 |
- Received the Marketing authorization (Regulatory Approval) for the “Digital Therapeutic App for Hypertension”.
|
June 2022 |
- Paper about cost-effectiveness of Digital Therapeutic App for Hypertension is published in Hypertension Research Journal.
|
August 2022 |
- A license agreement with Sawai Group Holdings for the development and marketing of a DTx solution in the NASH field.
|
September 2022 |
- Digital Therapeutic App for Hypertension: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
|
Norbember 2022 |
- Partnered with Fukusima Medical University to develop a Prescription Digital Therapeutic App for Chronic Low Back Pain
|
December 2022 |
- Clinical trial begins for the alcohol addiction treatment app.
|
January 2023 |
- "ascure Smoking Cessation," a fully online smoking cessation program, reaches 300 corporate installations.
|
June 2023 |
- Received Judging Committee's Special Award of Startup Award 2023 (NIPPON STARTUP AWARD)
|
September 2023 |
- Selected for the GSAP (Global Startup Acceleration Program) hosted by Alchemist and JETRO
|
October 2023 |
- Selected for the “J-Startup Impact” (startup development support program)sponsored by the Ministry of Internal Affairs and Communications.
- “ascure smoking cessation program” adopted as Osaka City’s smoking cessation support program
- Digital health program “ascure” is introduced to 350 corporate entities including Osaka City and other municipalities, corporate health insurance societies, and employers.
|
December 2023 |
- "2023 Japan Excellent Products and Service Award" Nikkei Industry Newspaper Award.
|
February 2024 |
- "The 5th IP BASE AWARD Startup Division” Encouragement Prize Winner.
- Started clinical trial for Prescription digital Therapeutic App for NASH (Non-Alcoholic Steatohepatitis).
|
May 2024 |
- Ranked in the” World's Best Digital Health Companies 2024” list
|